Sarcopenia Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Sarcopenia Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The global sarcopenia treatment market is estimated to be USD 2,746.5 million in 2021. It is expected to reach USD 3,684.1 million by 2027, registering a CAGR of 5.12% from 2022 to 2027.

The outbreak of COVID-19 showed an impact on the sarcopenia treatment market because healthcare services were significantly reduced due to social distancing measures taken by governments across the globe. Moreover, the COVID-19 pandemic affected the global economy and significantly impacted the functioning of general hospital care for non-COVID-19 patients in hospitals across the globe. An article titled "Skeletal Muscle Mass, Sarcopenia and Rehabilitation Outcomes in Post-Acute COVID-19 Patients" in the Journal of Clinical Medicine in November 2021 discussed the e impact of the existence of sarcopenia upon admission to a post-acute COVID-19 patient rehabilitation unit on body composition and functional and respiratory capacity at discharge. The article inferred that around 58% of the COVID-19 patients in rehabilitation centers were found to have sarcopenia. Various factors contributing to the onset of the disease include malnutrition, increased protein and energy requirements, weight loss, prolonged immobilization, low-calorie, and low-protein diet, low vitamin D level, inflammatory state, BMI, and age. Though the study's sample size is small and further trials are required, early diagnosis of sarcopenia could help manage the disease in the COVID-19 affected patients. Thus, due to the abovementioned factors, COVID-19 has impacted the sarcopenia treatment market. Hence, the studied market has depicted a slow growth over time.

The market is expected to grow due to the rising of the geriatric population, as with growing age, the chance of muscle weakness gets increases. As per the CDPAP.com, data updated in December 2021, the risk of disability is 1.5 to 4.6 times higher in older adults with sarcopenia than in older adults without sarcopenia. By the data from World Population Prospects: the 2021 Revision, By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Hence, the growing aging population and increasing interest in preventive healthcare results in the rising adoption of supplements is a major factor in boosting the demand for sarcopenia treatment.

However, the non-availability of new drugs significantly hinders the market's growth.

Protein is a critical macronutrient for the maintenance of normal bodily functions. Daily protein intake varies by age, sex, and degree of daily activity but is critical to maintaining muscle mass and strength throughout an individual's lifespan. Therefore, increasing protein intake in the diet will help prevent loss of muscle mass, thus driving the market.

The growing research and development activities are helping in identifying the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia will drive segmental growth. According to the study "Protein Source and Muscle Health in Older Adults: A Literature Review," published in February 2021, stated that higher dietary protein of up to 1.2 g/kg body weight/day might help prevent sarcopenia and maintain musculoskeletal health in older individuals. Whey and soy protein are the most common high-quality proteins, and there is growing consumer demand for additional plant-sourced dietary protein options.

Moreover, a research study was initiated in April 2022 to investigate the effect of consuming 12.5g (twice daily) of Blue Whiting Protein Hydrolysates daily in combination with exercise for eight weeks on whole body lean mass tissue and measures of muscle strength and functionality in free-living community-dwelling older adults. The positive results from this study will boost the protein intake for treating sarcopenia, thus leading to segment growth.

According to the study titled "Effects of Protein Supplementation and Exercise On Delaying Sarcopenia in Healthy Older Individuals in Asian And Non-Asian Countries: A Systematic Review and Meta-Analysis" published in March 2022, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Additionally, in February 2021, MYOS CORP received a patent from United States Patent and Trademark Office (USPTO) titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate". This patent is expected to protect advanced technologies related to improving skeletal muscle protein synthetic rate in older mammals by administering proprietary nutritional compositions such as MYOS' advanced nutrition product, Fortetropin. Such patent registration will bolster research activities in the segment, thus driving the market.

Hence, the rising research and development activities proving protein supplements efficacy in treating sarcopenia are likely to boost the market growth.

North America is expected to hold a dominant position in the sarcopenia treatment market, owing to the presence of developed healthcare facilities and technological advancements that are likely to fuel the growth of the sarcopenia treatment market during the forecast period.

The economic burden of sarcopenia-associated disability is considered in United States owing to the increased prevalence of the geriatric population, the presence of several major players, and increasing research and developments in the country.

For instance, the survey titled “Publication Trends for Sarcopenia in the World: A 20-Year Bibliometric Analysis” published online in February 2022 shows that United States Department of Health and Human Services was the leading funding organization that sponsored 1,604 sarcopenia-related articles, and United States is the leading country which contributes more towards sarcopenia related research and developments. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.

In February 2022, MyMD Pharmaceuticals announced positive clinical data before the upcoming Phase 2 Trial of MYMD-1 drug candidates. MYMD-1 is a novel immunotherapy drug developed with the primary purpose of slowing the aging process, preventing sarcopenia and frailty, and extending a healthy lifespan.

In January 2022, MyMD Pharmaceuticals, Inc. was awarded United States Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.” by United States Patent and Trademark Office (USPTO). This latest patent adds to MyMD’s intellectual property portfolio of 16 granted patents which covers MYMD-1 in methods of reversing the normal aging process and extending lifespan and treating chronic inflammation, autoimmune disorders, diabetes, multiple sclerosis (MS), viral infections, addictions, fibrosis, asthma, and other disorders. Therefore, owing to the aforementioned factors and the recent developments, the studied market is anticipated to grow in the region over the forecast period.

The key manufacturers in the sarcopenia treatment market have been focusing on novel marketing and sales strategies to increase their product penetration. Along with that, the rising inclination towards online distribution channels has been playing a vital role. A few key market players in the studied market are GlaxoSmithKline plc, Eli Lilly and Company, Nestlé S.A., Sanofi S.A., and Bayer AG, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support